Umifenovir, inhaled ciclesonide for outpatient treatment, long-term sequelae one year after COVID-19 hospitalisation

Peer reviewed journals featured:

- Randomised controlled trials of:
  - Umifenovir versus standard care in non-severe COVID-19 [here]
  - Inhaled ciclesonide for outpatient treatment [here]
- Observational studies on:
  - Long-term sequelae one year after hospitalisation for severe COVID-19 [here]
  - Factors associated with risk of postdischarge thrombosis in COVID-19 patients [here]
  - Impact of lockdowns on mobility [here]
  - Lateral flow immunoassay tests for SARS-CoV-2 antibodies [here]
  - Prospective validation of 4C prognostic models for hospitalised COVID-19 adults [here]
  - Saliva vs nasopharyngeal swabs for detecting SARS-CoV-2 in COVID-19 patients [here]
  - Single-swab sampling for rapid COVID-19 detection in outbreak settings [here]
- An editorial on preparing for out-of-season influenza epidemics when international travel resumes in Australia [here]

Letters and correspondence discussed:

- Mental health of high school students after COVID-19–associated remote schooling measures lifted in Austria [here]
- Understanding and tracking the impact of post-acute COVID-19 syndrome in the UK [here]

Guidance and reports:

- The World Health Organization published updated interim recommendations for use of Pfizer (Comirnaty) [here] and Spikevax (Moderna) [here] vaccines
- The Therapeutic Goods Administration (TGA):
  - Issued provisional determination for Medigen protein-based subunit COVID-19 vaccine [here]
  - Released information on international COVID-19 vaccines recognised for the purposes of travel to Australia [here]
News and blogs

- COVID-19 and pregnancy [here](#)
- Cuba’s bet on home-grown COVID-19 vaccines [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on COVID-19 transmission, SARS-CoV-2 vaccines, and variants of concern, post-acute sequelae of COVID-19 (PASC), surgery and COVID-19, rapid testing and risk mitigation strategies.